Study of AML genes and drug response in young patients
Part of Blood & lymphatic, Cancer clinical trials.
This trial looks at how childhood, teen, and young adult acute myeloid leukemia (AML) changes at the genetic level and how cells respond to multiple drugs. It may help doctors understand which treatments work best and how leukemia interacts with supportive cells in the bone marrow.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 0 and 25 years old
- You have AML (newly diagnosed or AML that came back/was hard to treat), or a known genetic risk for AML
- If you do not have AML and have no genetic risk, you must still be having a bone marrow sample as part of standard care
- A parent or legal guardian can sign consent if you’re under 18; if you’re 18 or older, you sign your own consent
- You must be able to join the study and not refuse participation
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how adults with acute myeloid leukemia (AML) are treated and how they fare over time. The goal is to better understand the disease and improve care.
This trial looks at blood and bone marrow samples from children and teens whose leukemia has come back or is hard to treat. The goal is to better understand the disease and guide future options for these patients.
This trial compares standard chemotherapy with newer drug combinations (CPX-351 and gilteritinib) for children and young adults with acute myeloid leukemia (AML), a type of blood cancer. It aims to find which treatment works better and who might benefit from targeted therapy based on specific genetic changes (FLT3 mutations).
This study looks at leukemia “genetic clues” using special stored samples, including cord blood saved at birth. It may help researchers better understand leukemia biology and how common mutations may show up early.
This trial tests different induction therapy options based on the specific genetic subtype of a child’s AML and how the leukemia responds early on. The goal is to personalize treatment to improve outcomes and reduce side effects.
This non-interventional study follows adults with acute myeloid leukemia (AML) to better understand the disease and how patients do in real-world care. It may help researchers compare outcomes across different types of AML, but you would not receive a study treatment just for joining.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.